Medial EarlySign Selects Chief Medical Officer Dr. Jeremy Orr as New CEO

Appointment Underscores AI Health Company’s Commitment to Providing Healthcare System-Ready Solutions

EarlySign (, a leader in machine learning-based solutions to aid in the early detection and prevention of high-burden diseases, today announced the appointment of Jeremy Orr, MD, MPH, as its new Chief Executive Officer.

Dr. Orr, who becomes CEO after serving as EarlySign’s Chief Medical Officer for the past year, succeeds company co-founder Ori Geva, who will remain with EarlySign as President and Director of Commercial Strategy.

“Experienced clinicians are essential in working with providers, researchers, and technologists and designing machine learning tools to improve the standard of care dramatically,” said Geva. “Jeremy’s background as a practicing physician, his rich experience in digital health, as well as his significant contribution as part of our executive team, will enable EarlySign to engage key players within the health ecosystem through the lens of someone who truly understands its challenges and processes. I’m excited to continue working with him as he leads EarlySign in the continued rollout of our clinically-validated AI-based platform to healthcare organizations across the U.S. and the world.”

Dr. Orr joined EarlySign as CMO in July 2018 and brings extensive experience in patient care, digital health, and public health as both a practicing physician and healthcare IT executive. His elevation to CEO represents EarlySign’s strategic evolution from a developer of technology to a customer and patient-centered solution provider and its continued commitment for high quality clinical solutions for the benefit of patients.

“Under Ori’s leadership, EarlySign has proven that Machine Learning technology applied to clinical data can help health care providers in their efforts to detect high burden health conditions much earlier than previously imagined,” said Dr. Orr.  “From an early stage, Ori has insisted on clinical rigor and validation.  This high standard opened the door to the key partnerships we have with leading health systems today.  I am excited to lead EarlySign to the next stage of our mission: to grow our presence worldwide and positively impact millions of lives.”

Since its founding in 2013, EarlySign has gained significant traction among global healthcare organizations, having solutions working in practice with leading health systems including Geisinger Health System, Kaiser Permanente, and SLUCare in the U.S., and Maccabi Healthcare Services in Israel. The company’s AI-based clinical solutions are currently used to identify patients at high risk of lower GI disorders, prediabetic progression to diabetes, downstream diabetic complications and chronic kidney disease (CKD). The company plans to launch solutions for several additional conditions and classes of decision support in the next 12 months.